CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CareDx reports solid Q4 earnings, eyes profitable growth in 2023

CareDx delivered strong financial results, focusing on profitable growth and strategic initiatives to drive revenue and market leadership.
While facing challenges such as fluctuating transplant volumes and market risks, the company is actively pursuing opportunities for expansion and innovation.
Overall, CareDx's performance, strengths, and proactive approach to challenges and opportunities position it for continued success and growth in the coming year.

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System

CareDx to Report Third Quarter 2022 Financial Results

CareDx Joins Forces with National Kidney Foundation and Honor the Gift Coalition to Host Immuno Bill Webinar for Kidney Transplant Patients

CareDx Presents Latest Data on AlloSeq NGS Solutions and Transplant Innovation at the American Society for Histocompatibility and Immunogenetics Annual Meeting

The introduction of new products and the further extension of reimbursement routes are projected to fuel CDNA growth. CDNA is renewing its emphasis on profitability after a widening loss caused a 14% share decline in August after the Q2 earnings release.

CareDx: Shaking Off First-Mover Disadvantage

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will host a symposium to describe the latest innovations in post-cardiac transplant care at the HFSA (Heart Failure Society of America) Annual Scientific Meeting 2022 taking place in Washington, D.C., September 30 - October 3.

CareDx to Host Symposium Covering Innovation in Multimodal Surveillance Including AiCAV for Post-Cardiac Transplant Care

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a new peer-reviewed publication showing that AlloMap®, the industry's only gene-expression profiling (GEP) blood test to non-invasively assess graft rejection by monitoring immune quiescence in heart transplant patients,1 resulted

Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is convening its annual digital health user conference, Management Expert Exchange in Transplantation (MEET), September 18-20 in Las Vegas, Nevada. The CareDx user conference brings together transplant administrators, qual

CareDx Showcases Transplant Digital Leadership in Patient Care at 2022 MEET Conference

Block

Cathie Wood-led Ark Investment Management has bought over 100,000 shares of Jack Dorsey's Block Inc (NYSE: SQ), valued at over $6.9 million based on Wednesday's closing price.

Cathie Wood's Ark Invest Adds $7M Of Bitcoin-Focused Block Shares, Also Picks Up Some CareDx Stock

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has served its 100,000th transplant patient, representing one out of ten patients transplanted in the U.S. This milestone demonstrates strong clinical adoption of molecular surveillance for transplant patients and showcase

CareDx Celebrates 1 Million Organ Transplants and 100,000 Patient Milestone

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading participation in the 29th International Congress of The Transplantation Society (TTS 2022) taking place September 10-14 in Buenos Aires, Argentina. Transplant physicians will present data from over 25 abstracts demonst

CareDx Demonstrates Global Leadership at 29th International Congress of The Transplantation Society

Wilmington, Delaware--(Newsfile Corp. - August 30, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of CareDx, Inc. (NASDAQ: CDNA) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-caredx-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating CareDx, Inc

Butterfly Network

Exact Sciences

All three of these businesses dominate the relatively new niches they operate in.

Cathie Wood Goes Bargain-Shopping: 3 Stocks She Just Bought

Cathie Wood-led Ark Investment Management loaded up on 153,917 shares of precision medicine company CareDx Inc (NASDAQ: CDNA), via the ARK Genomic Revolution ETF (NYSE: ARKG

CareDx (CDNA) – Cathie Wood's Ark Invest Adds $3M In CareDx Shares Despite Bleak Q2 Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will co-host, along with MOTTEP (Minority Organ Tissue Transplantation Education Program), a panel discussion, “Tackling Health Equity in Organ Transplantation,” on August 18, 2022, 10:00-11:00am PST (1:00–2:00pm EST). The

CareDx and MOTTEP Co-Host Health Equity Summit

Which of the healthcare diagnostic services producers is now a better buy to help build your portfolio's near-term capital value? Near-term only, repetition provides long term. Find out here what the best-informed, big-$ investors now think likely to happen (good and bad) in the next 3+ months to prices of several stocks now seen attractively priced.

CareDx: Best Near Cap-Gain Health Diagnostics Prospect Say Market Makers

CareDx, Inc. (NASDAQ:CDNA ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO Conference Call Participants Andrew Cooper - Raymond James Alex Nowak - Craig-Hallum Capital Group Brandon Couillard - Jefferies Jacob Johnson - Stephens Yi Chen - H.C. Wainwright E.V.

CareDx, Inc. (CDNA) CEO Reg Seeto on Q2 2022 Results - Earnings Call Transcript

CareDx (CDNA) delivered earnings and revenue surprises of -62.50% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Reports Q2 Loss, Lags Revenue Estimates

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today reported financial results for the second quarter ended June 30, 2022. Recent Highlights: Delivered 45,000 patient test results, representing growth of 21% compared to second quarter of 2021 Achieved revenue of $80.6 million, increasing 9%

CareDx Reports Second Quarter 2022 Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its AlloCare® mobile health app features expanded medication adherence and patient-provider communication capabilities resulting from the successful integration of MedActionPlan®, an acquisition made last year. MedActionPlan

CareDx Unveils New Patient-Centered Medication Management Features on AlloCare Mobile Health App

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the availability of AlloHome™, a pan-organ patient monitoring solution that extends care into a patient's home by capturing a range of vital health data that can help doctors with the early identification of adverse clinical event

CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. In

CareDx to Report Second Quarter 2022 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading participation and top spot, for the third year in a row, as a Distinguished Founder's Circle Sponsor for the 2022 American Society of Transplant Surgeons (ASTS) Summer Winter Symposium, taking place August 4-7, in Miam

CareDx Demonstrates Industry-Leading Commitment to Advancing Transplant Innovation as Distinguished Founder's Circle Sponsor for the 2022 American Society of Transplant Surgeons Symposium

NEW YORK , July 22, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/caredx-inc-loss-submission-form/?id=30072&from=4 This lawsuit is on behalf of all persons or entities who purchased CareDx common stock between February 24, 2021, and May 5, 2022.

CDNA SHAREHOLDER ALERT: Jakubowitz Law Reminds CareDx Shareholders of a Lead Plaintiff Deadline of July 22, 2022

New York, New York--(Newsfile Corp. - July 21, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased CareDx, Inc. ("CareDx") (NASDAQ: CDNA) . This lawsuit is on behalf of all persons or entities who purchased CareDx common stock between February 24, 2021, and May 5, 2022.If you suffered a loss, contact us at the link below. There is no cost...

News for CareDx Stock (CDNA)